Sarepta Therapeutics Inc (SRPT) 14.94 $SRPT
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015
Business Wire - Fri Jan 02, 11:39AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ:SRPT) securities between April 21, 2014 and October 27, 2014.
SRPT: 14.94 (+0.47)
Stull, Stull & Brody Announces the Investigation of Possible Breaches of Fiduciary Duties of Officers and Directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
GlobeNewswire - Wed Dec 31, 3:30PM CST
Attorney Advertising. Stull, Stull & Brody, a New York based law firm with offices in Beverly Hills that specializes in representing investors nationwide, announces that a federal securities fraud lawsuit has been filed and that it has commenced an investigation into possible breaches of fiduciary duty by the directors and officers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT).
SRPT: 14.94 (+0.47)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
GlobeNewswire - Mon Dec 29, 2:55PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) securities between April 21, 2014 and October 27, 2014.
SRPT: 14.94 (+0.47)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PTCT: 51.00 (-0.77), BIOD: 1.39 (+0.06)
SECURITIES ALERT: Rosen Law Firm Reminds Sarepta Therapeutics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - SRPT
GlobeNewswire - Wed Dec 24, 2:52PM CST
Rosen Law Firm reminds purchasers of Sarepta Therapeutics, Inc. stock (Nasdaq:SRPT) during the period from April 21, 2014 through October 27, 2014 of the important February 9, 2015 lead plaintiff deadline in the class action lawsuit.
SRPT: 14.94 (+0.47)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.32 (+0.06), RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), PTCT: 51.00 (-0.77)
Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 101.79 (+2.18), SRPT: 14.94 (+0.47), CPHD: 54.12 (-0.02), ALXN: 186.60 (+1.57), ALKS: 58.24 (-0.32)
Why Is George Soros Buying This Beaten Down Biotech Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Dec 21, 10:04AM CST
Source: Wikimedia Commons/ Niccolò Caranti The controversial billionaire and hedge fund guru George Soros is undoubtedly one of the best investors on the planet today. At age 83, he is estimated to be the seventh-richest American, with a net...
PFE: 31.33 (+0.18), AZN: 70.40 (+0.02), SRPT: 14.94 (+0.47), AMGN: 159.89 (+0.60), AEGR: 21.58 (+0.64), SNY: 45.52 (-0.09)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 342.01 (+2.56), VRX: 144.45 (+1.34), QLTI: 4.08 (+0.07), CTRX: 52.21 (+0.46), BCRX: 12.14 (-0.02), ACT: 259.13 (+1.72), MDT: 71.88 (-0.32), TKMR: 14.76 (-0.39), NEPT: 1.88 (-0.02), BSX: 13.22 (-0.03), AGN: 212.75 (+0.16), CMRX: 41.78 (+1.52), ALNY: 97.77 (+0.77), SRPT: 14.94 (+0.47), SHPG: 209.01 (-3.53), NLNK: 43.65 (+3.90), SNY: 45.52 (-0.09), MSLI: 1.63 (-0.02), NVCN: 6.50 (-0.32), CRME: 9.36 (+0.11), EBS: 26.90 (-0.33), GSK: 42.37 (-0.37), CELG: 113.52 (+1.66), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), NVDQ: 16.31 (-0.31), NVS: 92.25 (-0.41)
Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), MYL: 56.35 (-0.02)
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 91.26 (-0.46), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), SGMO: 15.27 (+0.06)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 2.32 (+0.06), RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), PTCT: 51.00 (-0.77)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), NBIX: 22.84 (+0.50), GILD: 94.91 (+0.65), ARWR: 7.71 (+0.33), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), CTIC: 2.40 (+0.04), CEMP: 22.89 (-0.62), BMY: 59.51 (+0.48)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 91.26 (-0.46), BMRN: 92.17 (+1.77), TGTX: 16.33 (+0.49), BMY: 59.51 (+0.48), MACK: 11.43 (+0.13), FMI: 22.18 (-0.04), RNA: 18.83 (+0.08), GWPH: 70.04 (+2.36), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), ICPT: 159.49 (+3.49), THLD: 3.43 (+0.25), CEMP: 22.89 (-0.62), NVS: 92.25 (-0.41)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), TKMR: 14.76 (-0.39), ABIO: 1.04 (+0.09)
Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 14.94 (+0.47), IBB: 306.34 (+2.99), ARIA: 6.89 (+0.02), CELG: 113.52 (+1.66)
With Mid-2015 NDA Submission, Sarepta Can Rise
Value Insight - at Seeking Alpha - Fri Dec 12, 8:35AM CST
BMRN: 92.17 (+1.77), SRPT: 14.94 (+0.47)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 21.17 (-0.78), CLDN: 20.17 (+0.64), BRID: 7.75 (+0.38), HCCI: 12.29 (-0.04), MIND: 5.85 (-0.08), ROSE: 22.55 (+0.24), OBAS: 6.95 (+0.01), MEIP: 4.33 (+0.06), IESC: 7.63 (-0.03), SRPT: 14.94 (+0.47), CONN: 18.79 (+0.10), LINE: 11.35 (+1.22), DGLY: 15.46 (+0.14)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015
Business Wire - Fri Jan 02, 11:39AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ:SRPT) securities between April 21, 2014 and October 27, 2014. SRPT: 14.94 (+0.47)
Stull, Stull & Brody Announces the Investigation of Possible Breaches of Fiduciary Duties of Officers and Directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
GlobeNewswire - Wed Dec 31, 3:30PM CST
Attorney Advertising. Stull, Stull & Brody, a New York based law firm with offices in Beverly Hills that specializes in representing investors nationwide, announces that a federal securities fraud lawsuit has been filed and that it has commenced an investigation into possible breaches of fiduciary duty by the directors and officers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(Nasdaq:SRPT). SRPT: 14.94 (+0.47)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
GlobeNewswire - Mon Dec 29, 2:55PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(Nasdaq:SRPT) securities between April 21, 2014 and October 27, 2014. SRPT: 14.94 (+0.47)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PTCT: 51.00 (-0.77), BIOD: 1.39 (+0.06)
SECURITIES ALERT: Rosen Law Firm Reminds Sarepta Therapeutics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - SRPT
GlobeNewswire - Wed Dec 24, 2:52PM CST
Rosen Law Firm reminds purchasers of Sarepta Therapeutics, Inc. stock (Nasdaq:SRPT) during the period from April 21, 2014 through October 27, 2014 of the important February 9, 2015 lead plaintiff deadline in the class action lawsuit.
SRPT: 14.94 (+0.47)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.32 (+0.06), RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), PTCT: 51.00 (-0.77)
Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 101.79 (+2.18), SRPT: 14.94 (+0.47), CPHD: 54.12 (-0.02), ALXN: 186.60 (+1.57), ALKS: 58.24 (-0.32)
Why Is George Soros Buying This Beaten Down Biotech Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Dec 21, 10:04AM CST
Source: Wikimedia Commons/ Niccolò Caranti The controversial billionaire and hedge fund guru George Soros is undoubtedly one of the best investors on the planet today. At age 83, he is estimated to be the seventh-richest American, with a net...
PFE: 31.33 (+0.18), AZN: 70.40 (+0.02), SRPT: 14.94 (+0.47), AMGN: 159.89 (+0.60), AEGR: 21.58 (+0.64), SNY: 45.52 (-0.09)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 342.01 (+2.56), VRX: 144.45 (+1.34), QLTI: 4.08 (+0.07), CTRX: 52.21 (+0.46), BCRX: 12.14 (-0.02), ACT: 259.13 (+1.72), MDT: 71.88 (-0.32), TKMR: 14.76 (-0.39), NEPT: 1.88 (-0.02), BSX: 13.22 (-0.03), AGN: 212.75 (+0.16), CMRX: 41.78 (+1.52), ALNY: 97.77 (+0.77), SRPT: 14.94 (+0.47), SHPG: 209.01 (-3.53), NLNK: 43.65 (+3.90), SNY: 45.52 (-0.09), MSLI: 1.63 (-0.02), NVCN: 6.50 (-0.32), CRME: 9.36 (+0.11), EBS: 26.90 (-0.33), GSK: 42.37 (-0.37), CELG: 113.52 (+1.66), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), NVDQ: 16.31 (-0.31), NVS: 92.25 (-0.41)
Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), MYL: 56.35 (-0.02)
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 91.26 (-0.46), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), SGMO: 15.27 (+0.06)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 2.32 (+0.06), RNA: 18.83 (+0.08), SRPT: 14.94 (+0.47), PFE: 31.33 (+0.18), PTCT: 51.00 (-0.77)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), NBIX: 22.84 (+0.50), GILD: 94.91 (+0.65), ARWR: 7.71 (+0.33), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), CTIC: 2.40 (+0.04), CEMP: 22.89 (-0.62), BMY: 59.51 (+0.48)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 91.26 (-0.46), BMRN: 92.17 (+1.77), TGTX: 16.33 (+0.49), BMY: 59.51 (+0.48), MACK: 11.43 (+0.13), FMI: 22.18 (-0.04), RNA: 18.83 (+0.08), GWPH: 70.04 (+2.36), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), ICPT: 159.49 (+3.49), THLD: 3.43 (+0.25), CEMP: 22.89 (-0.62), NVS: 92.25 (-0.41)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), TKMR: 14.76 (-0.39), ABIO: 1.04 (+0.09)
Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 14.94 (+0.47), IBB: 306.34 (+2.99), ARIA: 6.89 (+0.02), CELG: 113.52 (+1.66)
With Mid-2015 NDA Submission, Sarepta Can Rise
Value Insight - at Seeking Alpha - Fri Dec 12, 8:35AM CST
BMRN: 92.17 (+1.77), SRPT: 14.94 (+0.47)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 21.17 (-0.78), CLDN: 20.17 (+0.64), BRID: 7.75 (+0.38), HCCI: 12.29 (-0.04), MIND: 5.85 (-0.08), ROSE: 22.55 (+0.24), OBAS: 6.95 (+0.01), MEIP: 4.33 (+0.06), IESC: 7.63 (-0.03), SRPT: 14.94 (+0.47), CONN: 18.79 (+0.10), LINE: 11.35 (+1.22), DGLY: 15.46 (+0.14)
